Format

Send to

Choose Destination
Crit Rev Oncol Hematol. 2019 Dec;144:102815. doi: 10.1016/j.critrevonc.2019.102815. Epub 2019 Oct 5.

Emerging therapies in malignant pleural mesothelioma.

Author information

1
Department of Oncology, University Hospital of Udine, Italy; School of Medical Oncology, Department of Medicine, University of Udine, Italy. Electronic address: marika.cinausero@asuiud.sanita.fvg.it.
2
Department of Oncology, University Hospital of Udine, Italy; Department of Experimental, Diagnostic and Specialty Medicine - DIMES, University of Bologna, Italy.
3
Department of Oncology, University Hospital of Udine, Italy; School of Medical Oncology, Department of Medicine, University of Udine, Italy.
4
Department of Oncology, University Hospital of Udine, Italy.
5
Department of Oncology, Policlinico S. Orsola-Malpighi, University of Bologna, Bologna, Italy.

Abstract

Malignant pleural mesothelioma (MPM) is a rare cancer of the pleural surfaces frequently related to asbestos exposure. It is characterized by a poor prognosis even for patients treated with trimodality therapy, including surgery, chemotherapy and radiotherapy. Moreover, the majority of patients are not candidates for surgery due to disease advanced stage or medical comorbidities. For these patients, the survival rate is even lower and few therapeutic options are currently available. Nevertheless, many interesting novel approaches are under investigation, among which immunotherapy represents one of the most promising emerging strategies. In this review, we will discuss the role of new therapeutic options, particularly immunotherapy, and present the results of the most important and promising clinical trials.

KEYWORDS:

Anti-mesothelin therapy; Antiangiogenic therapy; Immunotherapy; Malignant pleural mesothelioma; Molecular; Target therapy

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center